Navigation Links
HMS Holdings Corp. Announces Q3 2008 Results, 2008 Revised Guidance and Initial 2009 Guidance
Date:10/31/2008

l be available at http://www.hmsholdings.com for at least a 12-month period. Shareholders and interested investors are welcome to contact HMSY Investor Relations at 212-857-5986. Following the filing of the Form 10-Q, corporate executives will be available to respond to inquiries from shareholders and interested investors.

About HMS Holdings Corp.

HMS Holdings Corp. (Nasdaq: HMSY) is the nation's leader in coordination of benefits and program integrity services for government healthcare programs. The company's clients include health and human services programs in more than 40 states, 80 Medicaid managed care plans, the Centers for Medicare and Medicaid Services (CMS), and Veterans Administration facilities. HMS helps ensure that healthcare claims are paid correctly and by the responsible party. As a result of the company's services, government healthcare programs recover over $1 billion annually, and avoid billions of dollars more in erroneous payments.

This press release includes presentations of earnings before interest, taxes, depreciation and amortization (EBITDA) and adjusted EBITDA. Adjusted EBITDA represents EBITDA adjusted for share-based compensation expense. EBITDA is a measure commonly used by the capital markets to value enterprises. Interest, taxes, depreciation and amortization can vary significantly between companies due in part to differences in accounting policies, tax strategies, levels of indebtedness and interest rates. Excluding these items provides insight into the underlying results of operations and facilitates comparisons between HMSY and other companies. EBITDA is also a useful measure of the Company's ability to service debt and is one of the m
'/>"/>

SOURCE HMS Holdings Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Hill-Rom Holdings, Inc. Invites You to Join Its Fiscal 2008 Fourth Quarter and Year End Earnings Webcast
2. XELR8 Holdings Announces Conference Call to Review Third Quarter Financial Results
3. China Pharma Holdings, Inc. to Initiate Clinical Trials For New Antibiotic Combination
4. HMS Holdings Corp. to Present at Oppenheimer 19th Annual Healthcare Conference
5. Lincare Holdings Inc. Announces Third Quarter and First Nine Months 2008 Financial Results
6. MINRAD International, Inc. Announces Change in Distribution Agreement with RxElite Holdings, Inc.
7. Z Trim Holdings, Inc. Releases Letter to Shareholders
8. Z Trim Holdings, Inc. Announces Private Placement Funding
9. MBF Healthcare Acquisition Corp. Amends Stock Purchase Agreement With Critical Homecare Solutions Holdings, Inc. to Extend Termination Date to October 31, 2008
10. Zimmer Holdings to Present at Thomas Weisel Partners Conference
11. HMS Holdings Corp. to Present at Thomas Weisel Partners 2008 Healthcare Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/8/2009)... A jury of 8 people in the W...unty woman $2,300,000 in pain and suffering for a ...y, James Tallman and Alicia Nocera of Thomas E. Cr...lf of the plaintiff, Vita Monestersky and against ...emergency total abdominal hysterectomy at age 18. ...
(Date:11/8/2009)..., Nation,s largest network of Hispanic health ad...are reform in 2009 ,, WASHINGTON, Nov. 7 /PRNe...epresentatives showed they have heard the voice of...th Care for America Act. Now the Senate must deliv...alth care reform," said Dr. Jane L. Delgado, Presi...
(Date:11/8/2009)..., Calls for Swift Passage of H.R. 3961 to Secure... Statement Attributable ...ical Association. ,, (Logo: http://www.newsco... AMA hails the passage of the House health reform ...r patients and physicians and calls for swift pass...
(Date:11/8/2009)..., Health Care Vote Shows Who Sides With Working ..., Pa., Nov. 8 On the he... Representatives for a good, balanced health care ... scoring of how our state,s U.S. representatives v...erica Act. ,, The legislation, which passed Sa...
(Date:11/7/2009)..., WASHINGTON, Nov. 7 K...h Insurance Plans (AHIP), released the following s..., "Health plans strongly support comprehensive hea...iscussion by proposing a complete overhaul of how ...e proposed guaranteed coverage, elimination of pre...
Breaking Medicine News(10 mins):Health News:Pennsylvania Jury Awards $2.3 Million to Fayette County Woman in Medical Malpractice Case 2Health News:National Alliance for Hispanic Health President and CEO Applauds House Action, Calls on Senate to Pass Health Reform in 2009 2Health News:AMA Hails House Passage of Health Reform Bill (H.R. 3962) 2Health News:Robert Brady (D-PA-1), Chaka Fattah (D-PA-2), Kathy Dahlkemper (D-PA-3), Joe Sestak (D-PA-7), Patrick Murphy (D-PA-8), Christopher Carney (D-PA-10), John Murtha (D-PA-12), Paul Kanjorski (D-PA-11), Allyson Schwartz (D-PA-13), Mike Doyle (D-PA-14) Ge 2Health News:AHIP Statement on House Passage of H.R. 3962 2
...headache stimuli also affect the appetite centre o...y loss of appetite often accompanies pain. People ...it is often assumed this must be because one commo...in the brain when pain takes away your appetite. F...
...nt risk factor for most cancers, says a Stanford U...ccur early in life are more likely to have a genet...re thyroid and testicular cancers, are even more l...re genes. The new model led him to a very ...
...cancer, a single raw clove of garlic can do wonde... Garlic is best known for staying off heart disea.... A substance called diallyl disulfide in garlic ...fide to rats and found it increased levels of the ...
...metimes.There has been a rise in the number of saf...heart rhythm. Many depend on either a pacemak...eart beating rhythimically. However sophisticated ...ings on heart devices issued by the Food and Drug ...
... have a common side effect- cough. Iron supplement...people on a widely-used blood pressure medication....ibitors are often used to treat high blood pressur...rious by doctors, but it is the most common reason...
...smaller babies tend to have lower IQs.While the di...ificance they might be of importance at a populati...ity have examined over 2500 children at age seven ...le factors such as the mother's age, race, educati...
Other Medicine News:
(Date:11/6/2009)...O, Nov. 6 Ardea Bioscien...y focused on the development of small-molecule the...man immunodeficiency virus (HIV), today reported r...e third quarter and nine months ended September 30...-bin/prnh/20091104/ARDEALOGO ) ,, "Since our la...
(Date:11/6/2009)... Nov. 6 GeoVax Labs, In...ompany"), an Atlanta-based, biopharmaceutical comp...by HIV-1 (Human Immunodeficiency Virus) and other ...er 2009 financial results and provided an operatio... and Chief Executive Officer commented, "We are pl...
(Date:11/6/2009)...S, November 6 , - Trial W...id for the,Treatment of Multi-Resistant Staphyloco...a speciality pharmaceutical company focused on the...signed to overcome the significant global,problem ...most advanced oral,antibacterial NXL103 (flopristi...
Breaking Medicine Technology:Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 2Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 3Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 4Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 5Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 6Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 7Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 8GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 2GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 3GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 4GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 5GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 6GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 7GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 8Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 3Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 4Lack of Good Sleep Might Be Deadly 48636 1Lack of Good Sleep Might Be Deadly 48636 2Lack of Good Sleep Might Be Deadly 48636 3GlobalEquityReport com Issues Cancer Stocks On The Move Today 3A HEB GNBT CTIC CTHP DNDN 48633 1GlobalEquityReport com Issues Cancer Stocks On The Move Today 3A HEB GNBT CTIC CTHP DNDN 48633 2Researchers at Case Western Reserve discover a new way the body fights fungal infection 48630 1Researchers at Case Western Reserve discover a new way the body fights fungal infection 48630 2
...sciences, Inc. (Nasdaq: RDEA ) today announced th...proof-of-concept monotherapy study of RDEA806,the ...erse transcriptase,inhibitor (NNRTI) for patients ...ing robust antiviral activity with a well-tolerate...ven today by Dr. Graeme Moyle, Director,of HIV Res...
...oteoTech),today announced that it has completed re...ts and has been cleared by the FDA to initiate its...ovel small molecule drug targeting,toxic beta-amyl...eimer,s,disease. ProteoTech initiated its Phase 1 ...ational Conference on Alzheimer,s disease in Chica...
Other Medicine Technology:Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference 2Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference 3Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference 4ProteoTech's Exebryl-1(R) Enters Human Clinical Trials for the Treatment of Alzheimer's Disease 2
9.00mm diameter Corneal Trephine Blades
8.75mm diameter Corneal Trephine Blades
8.25mm diameter Corneal Trephine Blades
7.50mm diameter Corneal Trephine Blades
Medicine Products: